– USA, CA – Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the addition of Dr. June Lee (M.D.) to its Board of Directors, replacing Dr. JJ Kang who will be stepping down after five years of service to focus on her current role as CEO of Appia Bio and as a Venture Partner at The Column Group.
“We are thrilled to welcome Dr. Lee to our Board at an important inflection point as we continue our transition towards becoming a clinical-stage company,” said CEO, Faraz Ali. “Dr. Lee brings a wealth of highly relevant strategic and operational development experience to Tenaya and is well-positioned to support us in our mission to bring new hope to individuals and families fighting both rare and prevalent forms of heart disease.”
About Dr. June Lee
Dr. Lee was most recently the Founder and CEO of Esker Therapeutics. She previously served as EVP, Chief Development Officer, and COO of MyoKardia from 2017 to 2020. In this role, Dr. Lee built and led a world-class global development organization to advance novel therapies for cardiomyopathies through clinical development. She was previously also therapeutic area head for early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech. She currently serves on the Advisory Board for Johns Hopkins University Center for Therapeutic Translation, serves as a Board Director for Eledon Pharmaceuticals Inc. and GenEdit, and is a member of the Scientific Advisory Board for Foresite Labs. Dr. Lee completed a Bachelor of Science in chemistry at Johns Hopkins University, an M.D. at the School of Medicine at the University of California, Davis, and her clinical training in internal medicine and pulmonary & critical care at UCLA and UCSF.
“I am very pleased to join Tenaya at such a pivotal time for the company and the entire field of precision medicine therapies for heart disease. I look forward to helping Tenaya realize the full potential of its differentiated science and capabilities in order to advance potentially transformative medicines through clinical development and towards future approvals,” commented Dr. Lee.
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine.
For more information: https://www.tenayatherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.